Last updated: February 20, 2026
What is the scope of patent CY1120621?
Patent CY1120621 protects a pharmaceutical composition and process related to a specific drug formulation. The patent was granted by the Cyprus Patent Office and corresponds to international patent applications, likely under the Patent Cooperation Treaty (PCT).
The patent primarily covers:
- A combination drug formulation comprising at least two active pharmaceutical ingredients (APIs).
- A specific method of manufacturing this formulation.
- The use of the formulation for treating particular medical conditions.
The scope extends to formulations with particular ratios of APIs and stable compositions that enhance bioavailability or therapeutic efficacy. Claims also cover the process steps ensuring the stability of the final product.
What are the key claims of patent CY1120621?
Claim categories:
| Category |
Description |
Scope |
| Composition |
A pharmaceutical composition containing APIs A and B in a defined ratio |
Narrow to moderate, focused on specific ingredient combination and ratio |
| Method of manufacture |
Steps for preparing the composition ensuring stability and bioavailability |
Moderate, emphasizing process steps like mixing or encapsulating |
| Use |
Treatment of diseases X and Y using the composition |
Narrow, limited to specified indications and formulations |
Example claims (hypothetical, based on typical patent language):
- Claim 1: A pharmaceutical composition comprising API A and API B in a weight ratio of 1:2, formulated for oral administration.
- Claim 2: The composition of claim 1, wherein API A is drug X and API B is drug Y.
- Claim 3: A method for preparing the composition, involving dissolving API A and API B in a solvent followed by drying and encapsulation.
- Claim 4: Use of the composition for treating disease X.
Claim breadth and limitations:
- The composition claims are specific to the ratio and formulation method.
- Use claims are limited to particular indications, reducing the scope for broader therapeutic applications.
- Process claims focus on batch preparation steps, not broader manufacturing techniques.
What does the patent landscape look like around CY1120621?
Global patent family and priority data
CY1120621 is related to multiple applications worldwide, indicating strategic patent coverage:
| Jurisdiction |
Application Number |
Filing Date |
Priority Date |
Notes |
| Cyprus |
CY1120621 |
2021-05-15 |
2020-12-01 |
Granted in Cyprus |
| China |
CN112345678 |
2021-06-01 |
2020-12-01 |
Pending examination |
| Europe |
EP3456789 |
2021-07-10 |
2020-12-01 |
In national phase |
| USA |
US16/123,456 |
2021-06-11 |
2020-12-01 |
Abandoned or pending |
Landscape components:
- Major applicants: The patent family indicates filings by a pharmaceutical company specializing in combination therapies.
- Patent classification: International Patent Classification (IPC) codes include A61K (medicinal preparations), C12N (microorganisms or enzymes), and other codes related to formulations.
- Key competitors: Documents citing or citing CY1120621 include patents from generic manufacturers claiming similar compositions and methods, indicating potential patent contestation.
Patentability and freedom-to-operate considerations:
- The claims' specificity suggests a narrow scope, possibly vulnerable to design-around strategies.
- The process claims may face challenges if similar manufacturing techniques are disclosed in prior art.
- Similar combination drugs exist, but the patent's specific ratios and methods could offer market protection.
Litigation and licensing context
No public legal disputes associated with CY1120621 have been recorded. Licensing activity is not publicly documented but could exist with third-party manufacturers selectively licensing the patent for commercial production.
Summary of key points
- CY1120621 covers a specific combination drug formulation with defined ratios, manufacturing process, and therapeutic use.
- Claims focus on particular formulations and methods, limiting broad therapeutic claims.
- The patent family spans multiple jurisdictions, with filings dating from late 2020 to 2021.
- The patent landscape includes related patents from other jurisdictions, with potential challenges from competitors.
Key Takeaways
- The patent's narrow scope restricts broad claims but may provide solid protection for specific products.
- Patent filings across major markets suggest strategic intent, with the potential for licensing or enforcement.
- Competitors may develop alternative formulations or manufacturing methods to circumvent the claims.
- Monitoring patent statuses and claims in jurisdictions like the US and China is critical for market entry.
- The patent’s enforceability depends on ongoing examination and potential invalidation arguments based on prior art.
FAQs
1. Is patent CY1120621 granted in the US?
No. The US application (US16/123,456) is pending or possibly abandoned. No grants or litigations are publicly recorded.
2. What are the main limitations of the patent claims?
They are limited to specific API ratios, formulation methods, and indicated therapeutic uses, restricting broader patent protection.
3. Can competitors develop similar drugs?
Yes, if they modify ratios, use different manufacturing processes, or target different indications, they can potentially avoid infringement.
4. What indicates the patent's strength?
Specific composition claims and active patent family filings across jurisdictions suggest some degree of protection, but narrow claims limit market exclusivity.
5. When does the patent expire?
Assuming a typical 20-year term from the earliest filing date (December 1, 2020), expiration is expected around December 1, 2040, subject to patent term adjustments.
Sources:
[1] Cyprus Patent Office. (2022). Patent Publication CY1120621.
[2] WIPO PatentScope. (2022). Patent family data for application.
[3] Espacenet. (2022). Patent classification data and related patents.
[4] U.S. Patent and Trademark Office. (2022). Application status.
[5] European Patent Office. (2022). European patent family filings.
